ARCHIVES

Graalman Objects To Criticism On Contract Competition

This article is from The Cancer Letter archive.

Vol. 03 No. 16 | April 22, 1977

Download PDF Visit The Full Archive

Related Articles

HER2+ Tumors Increase Risk Of Recurrence, Study Finds

November 27, 2009

Amgen Pays $24.9 Million To Settle Kickback Charges

April 19, 2013

DCPC Advisors Upset At NCAB Over Why Decision, But Move On

February 8, 1991

In Brief: Walter Lawrence, Reginald Ho Lead ACS; Henderson To Leave Dana-Farber for UCSF

November 22, 1991

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

IOM Report Calls For FDA Authority Nutritional Supplement Health Claims

May 21, 2010